Rani Therapeutics (RANI) Stock Price, News & Analysis

Company Overview

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Key Stats

• Today's Range: $1.65 to $1.76
• 50-Day Range: $1.25 to $1.85
• 52-Week Range: $1.24 to $8.75
• Volume: 227,473 shs
• Average Volume: 2.25 million shs
• Market Capitalization: $95.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.33
• Consensus Rating: Buy

Rani Therapeutics Stock Analysis - MarketRank™

Rani Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 259th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Rani Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rani Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rani Therapeutics are expected to grow in the coming year, from ($1.01) to ($0.84) per share.

Price to Book Value per Share Ratio

Rani Therapeutics has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.29% of the float of Rani Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rani Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rani Therapeutics has recently decreased by 5.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rani Therapeutics does not currently pay a dividend.

Dividend Growth

Rani Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.29% of the float of Rani Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rani Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rani Therapeutics has recently decreased by 5.97%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Rani Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Rani Therapeutics this week, compared to 2 articles on an average week.

Search Interest

15 people have searched for RANI on MarketBeat in the last 30 days. This is an increase of 1,400% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Rani Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,967.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

53.30% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.19% of the stock of Rani Therapeutics is held by institutions.

RANI Stock Analysis - Frequently Asked Questions

How have RANI shares performed this year?

Rani Therapeutics' stock was trading at $1.37 at the start of the year. Since then, RANI stock has increased by 21.2% and is now trading at $1.66.
View the best growth stocks for 2025 here.

How were Rani Therapeutics' earnings last quarter?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.03.

When did Rani Therapeutics IPO?

Rani Therapeutics (RANI) raised $100 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share.

Who are Rani Therapeutics' major shareholders?

Rani Therapeutics' top institutional investors include Two Sigma Investments LP (0.51%), Takeda Pharmaceutical Co. Ltd. (0.35%), Citadel Advisors LLC and Two Sigma Advisers LP (0.19%). Insiders that own company stock include South Cone Investments Limited, Talat Imran, Mir A Imran, Kate Mckinley and Cortes Isidoro Alfonso Quiroga.
View institutional ownership trends.

How do I buy shares of Rani Therapeutics?

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rani Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Honeywell International (HON), CrowdStrike (CRWD), Cisco Systems (CSCO), Intel (INTC) and Coca-Cola (KO).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 3/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RANI
• CUSIP: N/A
• CIK: 1856725
• Web: www.ranitherapeutics.com
• Phone: 408-457-3700
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.33
• High Stock Price Target: $17.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +643.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-33,970,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -219.64%
• Return on Assets: -56.71%

Debt

• Debt-to-Equity Ratio: 2.34
• Current Ratio: 1.60
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 3.25

Miscellaneous

• Outstanding Shares: 57,290,000
• Free Float: 26,754,000
• Market Cap: $95.10 million
• Optionable: Optionable
• Beta: 0.16